Skip to main content
letter
. 2023 Jan 16;29(4):554–556. doi: 10.1016/j.cmi.2023.01.008

Fig. 1.

Fig. 1

Postvaccination adverse reactions, as-needed medication, and inability to work following the second COVID-19 booster administration, separated by vaccine. (a) Rate of adverse reactions by subcategory. (b) Rate of as-needed medication. (c) Workability restrictions. Monovalent: BNT162b2 mRNA (n = 40), bivalent: BNT162b2 mRNA original/Omicron BA.4-5 (n = 64). Error bars indicate 95% CI. ∗∗∗: p < 0.001.